Gender-affirming hormone therapy and cardiovascular health in transgender adults

References

• Goodman M, Adams N, Corneil T, et al. Size and distribution of transgender and gender nonconforming populations: a narrative review. Endocrinol Metab Clin North Am. 2019;48(2):303–321. doi: 10.1016/j.ecl.2019.01.001.
   PubMed Web of Science ®Google Scholar
• Wiepjes CM, Nota NM, de Blok CJ, et al. The Amsterdam cohort of gender dysphoria study (1972–2015): trends in prevalence, treatment, and regrets. J Sex Med. 2018;15(4):582–590. doi: 10.1016/j.jsxm.2018.01.016.
   PubMed Web of Science ®Google Scholar
• Grant JM, Mottet L, Tanis JE, et al. National transgender discrimination survey report on health and health care: findings of a study by the National Center for Transgender Equality and the National Gay and Lesbian Task Force. Washington: National Center for Transgender Equality. 2010.
   Google Scholar
• Howerton I, Harris JK. Transgender identity and cardiovascular disease. Transgend Health. 2022;7(5):407–415. doi: 10.1089/trgh.2020.0188.
   PubMedGoogle Scholar
• Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health. 2022;23(Suppl 1):S1–S259. doi: 10.1080/26895269.2022.2100644.
   PubMedGoogle Scholar
• Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;23(12):1. doi: 10.4158/1934-2403-23.12.1437.
   Google Scholar
• Garofalo R. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Washington (DC): The National Academies Press; 2011.
   Google Scholar
• National Academies of Sciences, Engineering, and Medicine, Division of Behavioral and Social Sciences and Education, Committee on Population, et al. Understanding the well-being of LGBTQI + populations. Washington (DC): National Academies Press (US); 2020. doi: 10.17226/25877.
   Google Scholar
• Asscheman H, Giltay EJ, Megens JAJ, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164(4):635–642. doi: 10.1530/EJE-10-1038.
   PubMed Web of Science ®Google Scholar
• Van Kesteren PJM, Asscheman H, Megens JAJ, et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47(3):337–342. doi: 10.1046/j.1365-2265.1997.2601068.x.
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Andreasen AH, Jacobsen RK, et al. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29(21):2660–2668. doi: 10.1093/eurheartj/ehn408.
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340(jun03 4):c2519. doi: 10.1136/bmj.c2519.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428–432. doi: 10.1016/S0140-6736(03)14066-4.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Rifai N, Desindes S, et al. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab. 2008;93(5):1702–1710. doi: 10.1210/jc.2007-2193.
   PubMed Web of Science ®Google Scholar
• Nii S, Shinohara K, Matsushita H, et al. Hepatic effects of estrogen on plasma distribution of small dense low-density lipoprotein and free radical production in postmenopausal women. J Atheroscler Thromb. 2016;23(7):810–818. doi: 10.5551/jat.33175.
   PubMed Web of Science ®Google Scholar
• Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25. doi: 10.1210/jc.2007-1809.
   PubMed Web of Science ®Google Scholar
• Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989;18(1):49–57. doi: 10.1007/BF01579291.
   PubMed Web of Science ®Google Scholar
• Oriel KA. Clinical update: medical care of transsexual patients. J Gay Lesbian Med Assoc. 2000;4(4):185–194. doi: 10.1023/A:1026563806480.
   Google Scholar
• Prior JC. Progesterone is important for transgender women’s therapy—applying evidence for the benefits of progesterone in ciswomen. J Clin Endocrinol Metab. 2019;104(4):1181–1186. doi: 10.1210/jc.2018-01777.
   PubMed Web of Science ®Google Scholar
• Prior JC, Seifert-Klauss VR, Giustini D, et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. J Musculosk Neur Interact. 2017;17(3):146–154.
   PubMed Web of Science ®Google Scholar
• Manson JAE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353–1368. doi: 10.1001/jama.2013.278040.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi: 10.1161/CIRCULATIONAHA.106.642280.
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171–208. doi: 10.1210/er.2012-1008.
   PubMed Web of Science ®Google Scholar
• Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-Dysphoric/gender-Incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi: 10.1210/jc.2017-01658.
   PubMed Web of Science ®Google Scholar
• Deutsch MB. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people UCSF gender affirming health program, department of family and community medicine. San Francisco: University of California San Francisco; 2016.
   Google Scholar
• Xu JY, O’Connell MA, Notini L, et al. Selective estrogen receptor modulators: a potential option for non-binary gender-affirming hormonal care? Front Endocrinol (Lausanne). 2021;12:701364. doi: 10.3389/fendo.2021.701364.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Sabbah HN, Hauptman PJ, et al. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 2008;118(8):863–871. doi: 10.1161/CIRCULATIONAHA.107.760405.
   PubMed Web of Science ®Google Scholar
• Nagai M, Förster CY, Dote K. Sex hormone-specific neuroanatomy of takotsubo syndrome: is the insular cortex a moderator? Biomolecules. 2022;12(1):110. doi: 10.3390/biom12010110.
   PubMed Web of Science ®Google Scholar
• Dart AM, Du XJ, Kingwell BA. Gender, sex hormones and autonomic nervous control of the cardiovascular system. Cardiovasc Res. 2002;53(3):678–687. doi: 10.1016/s0008-6363(01)00508-9.
   PubMed Web of Science ®Google Scholar
• Mueller A, Haeberle L, Zollver H, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med. 2010;7(9):3190–3198. doi: 10.1111/j.1743-6109.2010.01912.x.
   PubMed Web of Science ®Google Scholar
• van Velzen DM, Paldino A, Klaver M, et al. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J Clin Endocrinol Metab. 2019;104(6):1937–1947. doi: 10.1210/jc.2018-02138.
   PubMed Web of Science ®Google Scholar
• Emi Y, Adachi M, Sasaki A, et al. Increased arterial stiffness in female-to-male transsexuals treated with androgen. J Obstet Gynaecol Res. 2008;34(5):890–897. doi: 10.1111/j.1447-0756.2008.00857.x.
   PubMed Web of Science ®Google Scholar
• Colizzi M, Costa R, Scaramuzzi F, et al. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study. J Psychosom Res. 2015;78(4):399–406. doi: 10.1016/j.jpsychores.2015.02.001.
   PubMed Web of Science ®Google Scholar
• Chandra P, Basra SS, Chen TC, et al. Alterations in lipids and adipocyte hormones in female-to-male transsexuals. Int J Endocrinol. 2010;2010:1–4. doi: 10.1155/2010/945053.
   Web of Science ®Google Scholar
• Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3914–3923. doi: 10.1210/jc.2017-01643.
   PubMed Web of Science ®Google Scholar
• SoRelle JA, Jiao R, Gao E, et al. Impact of hormone therapy on laboratory values in transgender patients. Clin Chem. 2019;65(1):170–179. doi: 10.1373/clinchem.2018.292730.
   PubMed Web of Science ®Google Scholar
• Allen AN, Jiao R, Day P, et al. Dynamic impact of hormone therapy on laboratory values in transgender patients over time. J Appl Lab Med. 2021;6(1):27–40. doi: 10.1093/jalm/jfaa192.
   PubMedGoogle Scholar
• Banks K, Kyinn M, Leemaqz SY, et al. Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension. 2021;77(6):2066–2074. doi: 10.1161/HYPERTENSIONAHA.120.16839.
   PubMed Web of Science ®Google Scholar
• Elbers JMH, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 2003;58(5):562–571. doi: 10.1046/j.1365-2265.2003.01753.x.
   PubMed Web of Science ®Google Scholar
• Wilson R, Spiers A, Ewan J, et al. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas. 2009;62(3):281–286. doi: 10.1016/j.maturitas.2009.01.009.
   PubMed Web of Science ®Google Scholar
• Gava G, Cerpolini S, Martelli V, et al. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol (Oxf). 2016;85(2):239–246. doi: 10.1111/cen.13050.
   PubMed Web of Science ®Google Scholar
• Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999–2011. doi: 10.1111/jsm.12571.
   PubMed Web of Science ®Google Scholar
• Shadid S, Abosi-Appeadu K, De Maertelaere AS, et al. Effects of gender-affirming hormone therapy on insulin sensitivity and incretin responses in transgender people. Diabetes Care. 2020;43(2):411–417. doi: 10.2337/dc19-1061.
   PubMed Web of Science ®Google Scholar
• Kyinn M, Banks K, Leemaqz SY, et al. Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy. Int J Obes (Lond). 2021;45(12):2562–2569. doi: 10.1038/s41366-021-00935-x.
   PubMed Web of Science ®Google Scholar
• James S, Herman J, Rankin S, et al. The report of the 2015 US transgender survey. Washington (DC): National Center for Transgender Equality; 2016.
   Google Scholar
• Wilson OWA, Jones BA, Bopp M. College student aerobic and muscle-strengthening activity: disparities between cis-gender and transgender students in the United States. J Am Coll Health. 2021;71(1):80–86. doi: 10.1080/07448481.2021.1876709.
   PubMedGoogle Scholar
• Bretherton I, Spanos C, Leemaqz SY, et al. Insulin resistance in transgender individuals correlates with android fat mass. Ther Adv Endocrinol Metab. 2021;12:2042018820985681. doi: 10.1177/2042018820985681.
   Web of Science ®Google Scholar
• Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169(4):471–478. doi: 10.1530/EJE-13-0493.
   PubMed Web of Science ®Google Scholar
• Spanos C, Bretherton I, Zajac JD, et al. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: a systematic review. World J Diabetes. 2020;11(3):66–77. doi: 10.4239/wjd.v11.i3.66.
   PubMed Web of Science ®Google Scholar
• Pirtea P, Ayoubi JM, Desmedt S, et al. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Fertil Steril. 2021;116(4):936–942. doi: 10.1016/j.fertnstert.2021.07.1206.
   PubMed Web of Science ®Google Scholar
• Lake JE, Miao H, Bowman ER, et al. Gender-affirming hormone therapy decreases d-dimer but worsens insulin sensitivity in transgender women. HIV Med. 2023;24:1144–1149.
   PubMed Web of Science ®Google Scholar
• Gava G, Mancini I, Alvisi S, et al. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen. Eur J Endocrinol. 2020;183(6):561–569. doi: 10.1530/EJE-20-0370.
   PubMed Web of Science ®Google Scholar
• Klaver M, de Mutsert R, van der Loos M, et al. Hormonal treatment and cardiovascular risk profile in transgender adolescents. Pediatrics. 2020;145(3):e20190741. doi: 10.1542/peds.2019-0741.
   PubMed Web of Science ®Google Scholar
• van Velzen D, Wiepjes C, Nota N, et al. Incident diabetes risk is not increased in transgender individuals using hormone therapy. J Clin Endocrinol Metab. 2021;107(5):e2000–e2007. doi: 10.1210/clinem/dgab934.
   Web of Science ®Google Scholar
• Nokoff NJ, Scarbro SL, Moreau KL, et al. Body composition and markers of cardiometabolic health in transgender youth on Gonadotropin-Releasing hormone agonists. Transgend Health. 2021;6(2):111–119. doi: 10.1089/trgh.2020.0029.
   PubMedGoogle Scholar
• Islam N, Nash R, Zhang Q, et al. Is there a link between hormone use and diabetes incidence in transgender people? Data from the STRONG cohort. J Clin Endocrinol Metabol. 2021;107(4):e1549–e1557. doi: 10.1210/clinem/dgab832.
   Web of Science ®Google Scholar
• Meng L-B, Zhang Y-M, Luo Y, et al. Chronic stress a potential suspect zero of atherosclerosis: a systematic review. Front Cardiovasc Med. 2021;8:738654. doi: 10.3389/fcvm.2021.738654.
   PubMed Web of Science ®Google Scholar
• Gulanski BI, Flannery CA, Peter PR, et al. Compromised endothelial function in transgender men taking testosterone. Clin Endocrinol (Oxf). 2020;92(2):138–144. doi: 10.1111/cen.14132.
   PubMed Web of Science ®Google Scholar
• Davezac M, Buscato M, Zahreddine R, et al. Estrogen receptor and vascular aging. Front Aging. 2021;2:727380. doi: 10.3389/fragi.2021.727380.
   PubMedGoogle Scholar
• Zhong X, Sun Y, Lu Y, et al. Immunomodulatory role of estrogen in ischemic stroke: neuroinflammation and effect of sex. Front Immunol. 2023;14:1164258. doi: 10.3389/fimmu.2023.1164258.
   PubMed Web of Science ®Google Scholar
• Aranda G, Mora M, Hanzu FA, et al. Effects of sex steroids on cardiovascular risk profile in transgender men under gender affirming hormone therapy. Endocrinol Diabetes Nutr (Engl Ed). 2019;66(6):385–392. doi: 10.1016/j.endien.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Iannantuoni F, Salazar JD, Martinez de Marañon A, et al. Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men. Fertil Steril. 2021;115(2):483–489. doi: 10.1016/j.fertnstert.2020.08.002.
   PubMed Web of Science ®Google Scholar
• Chekir C, Emi Y, Arai F, et al. Altered arterial stiffness in male-to-female transsexuals undergoing hormonal treatment. J Obstet Gynaecol Res. 2012;38(6):932–940. doi: 10.1111/j.1447-0756.2011.01815.x.
   PubMed Web of Science ®Google Scholar
• de Blok CJ, Wiepjes CM, van Velzen DM, et al. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. Lancet Diabetes Endocrinol. 2021;9(10):663–670. doi: 10.1016/S2213-8587(21)00185-6.
   PubMed Web of Science ®Google Scholar
• Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019;139(11):1461–1462. doi: 10.1161/CIRCULATIONAHA.118.038584.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–117. doi: 10.1056/NEJMoa2215025.
   PubMed Web of Science ®Google Scholar
• Alzahrani T, Nguyen T, Ryan A, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005597.
   PubMed Web of Science ®Google Scholar
• Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169(4):205–213. doi: 10.7326/M17-2785.
   PubMed Web of Science ®Google Scholar
• Fredriksen-Goldsen KI, Cook-Daniels L, Kim HJ, et al. Physical and mental health of transgender older adults: an at-risk and underserved population. Gerontologist. 2014;54(3):488–500. doi: 10.1093/geront/gnt021.
   PubMed Web of Science ®Google Scholar
• Ong C, Liu M, Thermidor S, et al. Transgender cardiovascular health: practical management for the clinician. Curr Atheroscler Rep. 2022;24(9):721–730. doi: 10.1007/s11883-022-01047-1.
   PubMed Web of Science ®Google Scholar